2025年8月13日下午，中关村发展集团召开干部大会，宣布北京市委、市政府关于中关村发展集团主要 领导任职的决定：李妍同志任中关村发展集团股份有限公司党委书记、董事长，杨仁全同志任中关村发 展集团股份有限公司党委副书记、董事、总经理。有关市领导，市委组织部、市国资委相关领导及处室 负责人，中关村发展集团领导班子成员、总部各部门正副职和子公司主要负责人参加会议。 来源：中关村发展集团 转自：北京日报客户端 中关村发展集团召开干部大会宣布主要领导任职决定 ...

Group 1 - The company held an investor relations event on August 13, attracting major institutions like Tianfeng Securities and Caitong Fund, where executives detailed the company's product layout and answered questions [1] - The focus of the event included the company's layout in narcotic drugs, market prospects for existing products, and exploration results in cutting-edge fields like mRNA [1] Group 2 - The company has accelerated its narcotic drug layout, with the sublingual tablet of dihydroetorphine hydrochloride being a key product, showing high growth potential [2] - The company has accumulated extensive experience in abuse-resistant sustained-release formulations, which are applied in multiple product developments [2] - The strict regulation of narcotic drugs creates a unique competitive barrier for companies like the company, which is one of the few manufacturers in this field [3] Group 3 - The company has identified significant market opportunities for its dihydroetorphine hydrochloride injection, projecting a 742.22% year-on-year revenue growth for 2024 [3] - The company is the only domestic pharmaceutical enterprise with integrated advantages in raw materials and formulations for dihydroetorphine hydrochloride [3] - The company has established partnerships with other formulation companies to enhance its market position in the raw material market [3] Group 4 - The company is also enhancing its narcotic drug portfolio, with the recent approval of a generic version of tramadol injection, strengthening its market competitiveness [4] Group 5 - The company's mature products, such as bisoprolol fumarate and benidipine hydrochloride, remain important revenue pillars, with the latter capturing a 55% market share in 2022 [5] - The new collection rules for centralized procurement allow for more competitive pricing strategies, which may benefit the company's main products [5] - The company is actively expanding its research and development, including studies on new indications for existing products [6] Group 6 - The company is exploring the mRNA vaccine field, with its self-built platform showing promising results in antigen design and thermal stability [6] - The company aims to establish itself as an "innovative pharmaceutical group" through continuous improvement in its narcotic drug matrix and mRNA vaccine exploration [6]

中关村发布公告称，2025年8月13日，中关村接受天风证券等投资者调研，公司副总裁范秀君、副总裁 兼董事会秘书黄志宇、证券事务代表胡秀梅参与接待，并回答了投资者提出的问题。 （文章来源：每日经济新闻） ...

Group 1: Pain Management and Drug Mechanism - The mechanism of action for dihydroetorphine hydrochloride is more targeted compared to traditional opioids like fentanyl, as it has a significantly higher affinity for mu-opioid receptors [2] - The technology for sustained-release or modified-release formulations is universal and not specific to a single drug, with experience in conventional and abuse-deterrent formulations [2] Group 2: Addiction and Abuse Risk - The addiction and abuse potential of analgesics is closely related to their pharmacological effects, rather than their pharmacokinetics or metabolic pathways, indicating the importance of drug release control and individualized dosing [3] Group 3: Antivertigo Drug Development - The central mechanism of action for phenylpropanolamine hydrochloride involves blocking acetylcholine at M and N receptors, resulting in central and peripheral anticholinergic effects [4] - Research is ongoing to expand indications beyond motion sickness, targeting conditions like Meniere's disease and vestibular neuritis [5] Group 4: Weight Management Drug Comparison - Naltrexone is the only approved drug for weight management in China, acting by antagonizing opioid receptors to suppress eating impulses, differing from the overseas combination product Contrave [6][7] Group 5: mRNA Vaccine Development - The mRNA vaccine utilizes an LNP delivery system, achieving high immunogenicity through a combination of delivery system optimization, antigen design, and immune strategy [8] - The company claims advantages in antigen design, immune durability, and thermal stability compared to competitors, although there is currently no IND or clinical submission timeline [8]

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Duoduo Pharmaceutical, has successfully passed the consistency evaluation for Tramadol Hydrochloride Injection, enhancing its market competitiveness and operational performance [1][5]. Group 1: Drug Approval and Details - Duoduo Pharmaceutical received the approval notice for Tramadol Hydrochloride Injection (2ml:100mg) from the National Medical Products Administration [1][2]. - The drug is classified as a chemical drug and is indicated for moderate to severe pain [3][4]. - The consistency evaluation approval allows for changes in the drug formulation, production process, and quality standards [2][4]. Group 2: Market Context and Financial Impact - In 2024, the sales revenue of Tramadol Hydrochloride Injection in domestic sample hospitals was 230 million yuan, with 93 million yuan in the first quarter of 2025 [4]. - Duoduo Pharmaceutical is the sixth company to pass the consistency evaluation for this drug, following five other companies [4]. - The company has invested 7.15 million yuan in research and development for this drug's consistency evaluation project [4]. Group 3: Future Prospects - The approval of Tramadol Hydrochloride Injection is expected to improve the company's market position and operational results [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug lifecycle [5].

Group 1 - The company is collaborating with Zhongguancun Intelligent Research Institute to launch the "Environmental Intelligent Cloud" and "Smart Fire Model" projects, aiming to transition from traditional operations to data-driven approaches [2] - Hanbang High-Tech (300449.SZ) confirmed its involvement in the intelligent service sector, focusing on digital intelligence business through technical cooperation with Zhongguancun Intelligent Research Institute in vertical industry applications [2] - The company is the sole technical solution provider and deep partner for the Environmental Intelligent Cloud project, offering services such as industry research, solution design, intelligent industrial control platform construction, and algorithm development for intelligent control modules [2]

（文章来源：证券日报） 证券日报网讯 8月12日晚间，中关村发布公告称，近日，公司下属公司多多药业收到国家药品监督管理 局核准签发的《药品注册证书》，获悉，多多药业研制的"盐酸氨溴索注射液"通过了药品注册审评审 批。 ...

（编辑 姚尧） 证券日报网讯 8月12日晚间，中关村发布公告称，近日，公司下属公司多多药业有限公司（简称：多多 药业）收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，获悉，多多药业生产的"盐 酸曲马多注射液"（规格：2ml：100mg）通过了仿制药质量和疗效一致性评价。 ...

公司监事会于2025年8月12日收到罗飞飞提交的辞任函，因工作变动，罗飞飞提请辞去公司监事会主席 及股东代表监事职务，即日生效。 鉴于张健的辞任，董事会经考虑董事会提名委员会的意见后，决议建议委任徐景泉及杨鹏艳为第二届董 事会执行董事(建议委任董事)。 中关村科技租赁(01601)发布公告，该公司宣布董事会于2025年8月12日，收到张健及韦廷权的书面辞 呈，张健因工作变动，辞去公司董事长、非执行董事、提名委员会主席、薪酬委员会委员、风险控制委 员会委员及环境、社会及管治委员会主席职务，韦廷权因工作变动，辞去公司非执行董事及审核委员会 委员职务。 张健及韦廷权的请辞已被董事会接纳。鉴于公司的法定代表人由公司董事长担任，张健将继续履职，直 至公司新任法定代表人任职生效。韦廷权已辞任公司非执行董事及审核委员会委员，自2025年8月12日 生效。 ...